Cambridge-based Sarepta Therapeutics said it was halting shipments of its Duchenne muscular dystrophy gene therapy for ...

Another person treated with Elevidys suffered acute liver failure, leading Sarepta to discontinue treatment in certain patients while it evaluates new safety precautions.

Investing.com -- BMO Capital and Piper Sandler downgraded Sarepta Therapeutics (NASDAQ: SRPT) after the company reported a second death linked to its gene therapy Elevidys in a non-ambulatory Duchenne ...

In today's Pharmalittle roundup, we're reading about a Sarepta setback with its Duchenne drug, the FDA workload causing a ...

Investors are regaining some appetite for risk amid rising optimism that the conflict won't spill over into a broader ...

Sarepta Therapeutics Inc. plummeted in early trading after reporting a second patient died of acute liver failure while being treated with its gene therapy for a rare muscle disorder.

The PPMD Annual Conference brings together families, researchers, clinicians, and companies committed to improving outcomes for people living with Duchenne. Satellos will be onsite to engage with the ...

TTAM Research Institute, the nonprofit led by 23andMe's former CEO Anne Wojcicki, has won back 23andMe’s core assets: its Personal Genome Service, Research Services, and telehealth subsidiary Lemonaid ...